WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/057811    International Application No.:    PCT/JP2008/070153
Publication Date: 07.05.2009 International Filing Date: 29.10.2008
C07D 401/12 (2006.01), C07D 403/12 (2006.01), A61K 31/444 (2006.01), A61K 31/506 (2006.01), A61P 1/16 (2006.01)
Applicants: OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP) (For All Designated States Except US).
SUMIDA, Takumi [JP/JP]; (JP) (For US Only).
TABUSA, Fujio [JP/JP]; (JP) (For US Only).
SEKIGUCHI, Kazuo [JP/JP]; (JP) (For US Only).
KODAMA, Takeshi [JP/JP]; (JP) (For US Only).
YASUMURA, Koichi [JP/JP]; (JP) (For US Only).
KOJIMA, Yutaka [JP/JP]; (JP) (For US Only).
MOTOYAMA, Masaaki [JP/JP]; (JP) (For US Only).
MIYAJIMA, Keisuke [JP/JP]; (JP) (For US Only).
YOSHIDA, Kenji [JP/JP]; (JP) (For US Only).
KAN, Keizo [JP/JP]; (JP) (For US Only).
SAKAMOTO, Makoto [JP/JP]; (JP) (For US Only).
TAKASU, Hideki [JP/JP]; (JP) (For US Only).
NAKAGAWA, Takashi [JP/JP]; (JP) (For US Only).
OHI, Naoto [JP/JP]; (JP) (For US Only).
HARADA, Yasuo [JP/JP]; (JP) (For US Only).
HASHIMOTO, Norikazu [JP/JP]; (JP) (For US Only).
MATSUYAMA, Hironori [JP/JP]; (JP) (For US Only).
IIDA, Masatoshi [JP/JP]; (JP) (For US Only).
FUJITA, Shigekazu [JP/JP]; (JP) (For US Only).
FUKUSHIMA, Tae [JP/JP]; (JP) (For US Only)
Inventors: SUMIDA, Takumi; (JP).
TABUSA, Fujio; (JP).
KODAMA, Takeshi; (JP).
YASUMURA, Koichi; (JP).
KOJIMA, Yutaka; (JP).
MOTOYAMA, Masaaki; (JP).
MIYAJIMA, Keisuke; (JP).
YOSHIDA, Kenji; (JP).
KAN, Keizo; (JP).
SAKAMOTO, Makoto; (JP).
TAKASU, Hideki; (JP).
NAKAGAWA, Takashi; (JP).
OHI, Naoto; (JP).
HARADA, Yasuo; (JP).
HASHIMOTO, Norikazu; (JP).
MATSUYAMA, Hironori; (JP).
IIDA, Masatoshi; (JP).
FUJITA, Shigekazu; (JP).
Agent: Saegusa & Partners; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku Osaka-shi, Osaka, 5410045 (JP)
Priority Data:
2007-281601 30.10.2007 JP
2007-336157 27.12.2007 JP
Abstract: front page image
(EN)The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5-Z1-, etc., Z1 is a lower alkylene group, etc., and R5 is a group represented by General Formula; wherein R13 is a hydrogen atom, etc., m is an integer from 1 to 5; R2 is a hydrogen atom: Y is CH or N: A1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group -CO-, etc.: R3 is a hydrogen atom, etc.: R4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R3 and R4, together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.
(FR)L'invention porte sur un composé hétérocyclique représenté par la formule générale (1): dans laquelle R1 est un groupe R5-Z1-, etc.; Z1 est un groupe alkylène inférieur, etc.; et R5 est un groupe représenté par la formule générale: dans laquelle R13 est un atome d'hydrogène, etc.; m est un entier de 1 à 5; R2 est un atome d'hydrogène; Y est CH ou N; A1 est un noyau hétérocyclique choisi dans le groupe composé des groupes indolediyle, le noyau hétérocyclique pouvant comprendre au moins un substituant; T est un groupe -CO-, etc.; R3 est un atome d'hydrogène, etc.; R4 est un groupe alkyle inférieur facultativement substitué par un ou plusieurs groupes hydroxy, etc.; R3 et R4, avec l'atome d'azote auquel ils sont liés, peuvent se lier l'un à l'autre et former un noyau hétérocyclique saturé de 5 à 10 chaînons, le noyau hétérocyclique pouvant comprendre au moins un substituant. Le composé hétérocyclique de l'invention possède d'excellents effets suppresseurs de la production du collagène et/ou de traitement des tumeurs.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)